Search PubMed⌕ Search

Biomedical subjects

J Morganroth

Publications and source records attributed to J Morganroth.

211 records · Page 12Linked to original sources
PubMed1972

Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase.

The cytotoxic action of lymphocytes upon cells bearing alloantigens to which they are sensitized is inhibited by agents that elevate intracellular amounts of 3':5'-cyclic AMP: prostaglandin E(1), cholera toxin, and theophylline. Cholinergic agents, added in the range of 1 to 100 pM, enhance cytotoxicity, an effect that is blocked by atropine. Because cholinergic agents elevate cyclic GMP in other in vitro systems, these findings suggest that the cytotoxic process effected by sensitized lymphocytes is a secretory phenomenon modulated by cyclic AMP and cyclic GMP.

Acetylcholine↗
PubMedDate not supplied

Large Mobile pedunculated left ventricular thrombus: identification by two-dimensional echocardiography.

Two-dimensional echocardiography has permitted the noninvasive detection and determination of the course of the natural history of left ventricular thrombus. In this report we cite an illustrative case of the development of a large pedunculated mobile left ventricular thrombus in the setting of idiopathic congestive cardiomyopathy. A fatal cerebral embolization occurred despite full-dose intravenous anticoagulation before left ventricular thrombectomy could be performed. The presence of a large mobile pedunculated left ventricular thrombus in the setting of embolization and adequate anticoagulation may require surgical intervention.

Aged↗
PubMedDate not supplied

Short- and long-term therapeutic efficacy of quinidine sulfate for the treatment of chronic ventricular arrhythmias.

To determine the efficacy and tolerance of oral quinidine sulfate in the treatment of chronic ventricular arrhythmias using contemporary definitions of drug efficacy, 20 ambulatory patients underwent a short-term, placebo-controlled, double-blind trial consisting of four days of quinidine therapy at 400 mg every 6 hours. A long-term trial was conducted in 12 additional patients where ventricular ectopic frequency during two weeks of placebo therapy was compared with that during eight weeks on quinidine sulfate at 300 mg every 6 hours. Quinidine efficacy was determined by 48 hours of Holter monitoring. Blood levels were within the therapeutic range in both trials. Side effects consisted of diarrhea, which occurred in 15 per cent of patients on the short-term and 25 per cent of patients on the long-term trial. Drug effect defined as a statistically significant (P less than 0.025) reduction in chronic premature ventricular complexes occurred in 70 per cent of patients on the short-term trial and in 67 per cent of patients on the long-term trial. In both trials, all patients with ventricular tachycardia had statistically significant suppression. Statistically significant reduction in ventricular couplets occurred in all patients on the short-term trial but in only 73 per cent of the patients on the long-term trial. These data can be used as reference standards for quinidine sulfate in new antiarrhythmic drug comparison trials.

Aged↗
PubMedDate not supplied

Pharmacokinetics of oral cibenzoline in arrhythmia patients.

The pharmacokinetics of oral cibenzoline were studied in 30 arrhythmia patients as part of an ascending multiple-dose efficacy study. The elimination half-life of the drug following repetitive dosing ranged from 7.6 to 22.3 hours, with a harmonic mean of 12.3 hours (n = 24), and increased with age and decreasing renal function. The drug exhibited apparent dose proportional and linear pharmacokinetics over the range of doses studied. Multivariate analysis revealed that the patients' age and serum creatinine concentration accounted for 71% of the variability in the range of beta values (terminal elimination rate constant), and that 69.5% of the intersubject variability in the steady-state trough plasma concentrations could be accounted for by the patients' age, weight and serum creatinine concentration. These data suggest that, although there is some intersubject variability in the elimination and accumulation of cibenzoline, much of the variability can be explained by the patients' age, weight and renal function.

Administration, Oral↗